AUTHORS
Juan Yue, PhD, Youqin Feng, MD2, Yinghui Yu, PhD3, Yongxian HU, MD4, He Huang, PhD5
AFFILIATIONS
1 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
2 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
3 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
4 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
5 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
ABSTRACT
Background
BCMA-directed chimeric antigen receptor-T cell therapy improves outcomes in relapsed/refractory multiple myeloma (RRMM), but response durability remains heterogeneous. We characterized peripheral blood cell reconstitution before and after BCMA CAR-T therapy and examined its associations with CAR-T expansion and clinical outcomes.
Methods
This single-center retrospective cohort study included 141 patients with RRMM treated with BCMA CAR-T cells; 115 had longitudinal blood cell data and were included in the hematologic analyses. Absolute counts and percentages of leukocyte subsets were collected before lymphodepletion, after lymphodepletion but before infusion, and at weeks 1 and 2 and month 1 after infusion. Longitudinal changes and associations with peak CAR-T expansion were assessed. Fine–Gray models evaluated disease progression and myeloma-related mortality, treating death without progression and non-myeloma-related death as competing events, respectively. Multivariable models adjusted for extramedullary disease, elevated lactate dehydrogenase, and prior lines of therapy.
Results
Among the 141 enrolled patients, 134 were evaluable for response. The objective response rate was 94.8%, the complete response rate was 50.7%. Among patients included in the blood cell analyses, distinct patterns of depletion and recovery were observed across leukocyte subsets after lymphodepleting chemotherapy. Median absolute lymphocyte and monocyte counts decreased by 96% and 87%, respectively, representing substantially greater reductions than those observed for neutrophils. The lymphocyte nadir occurred after lymphodepletion and before CAR-T cell infusion, whereas the neutrophil nadir occurred 1 week after infusion. The most pronounced hematologic recovery occurred between weeks 1 and 2 after infusion: the median absolute lymphocyte count increased from 0.30×10?/L to 1.10×10?/L, while the median lymphocyte percentage increased from 20.9% to 41.0%, indicating the emergence of an early lymphocyte-predominant reconstitution pattern.
At week 2, lymphocyte percentage was positively correlated with peak CAR-T cell expansion (Spearman ρ= 0.54, P < 0.001), whereas neutrophil percentage was inversely correlated with peak expansion (ρ= −0.56, P < 0.001). Patients who achieved complete response had a higher lymphocyte percentage and a lower neutrophil percentage at week 2 than those who did not achieve complete response. These findings suggest that early lymphocyte predominance may primarily reflect the magnitude of in vivo CAR-T cell expansion rather than serve as an independent predictor of treatment response.
Competing-risk analysis showed that a higher pre-lymphodepletion lymphocyte percentage was associated with a lower risk of myeloma-related death. Each doubling of the pre-lymphodepletion lymphocyte percentage was associated with a 34% reduction in the subdistribution hazard of myeloma-related death (SHR = 0.66, 95% CI 0.50–0.87; P = 0.003). This association remained significant after adjustment for extramedullary disease, elevated lactate dehydrogenase, and the number of prior treatment lines (adjusted SHR = 0.70, 95% CI 0.53–0.92; P = 0.011). Using 35% as an exploratory cutoff, patients with a pre-lymphodepletion lymphocyte percentage >35% had a lower 2-year cumulative incidence of myeloma-related death than those with a percentage ≤35% (15.8% vs 36.4%; SHR = 0.46, P = 0.023). In addition, a higher pre-lymphodepletion absolute lymphocyte count was associated with an earlier time to peak CAR-T cell expansion.
Conclusions
Peripheral blood recovery after BCMA CAR-T therapy followed a stage-specific pattern, with profound lymphocyte depletion after lymphodepletion, a neutrophil nadir at week 1, and lymphocyte-predominant reconstitution at week 2. Week 2 lymphocyte predominance reflected in vivo CAR-T expansion, whereas a higher pre-lymphodepletion lymphocyte percentage was independently associated with lower myeloma-related mortality. This routinely available measure may represent a simple candidate biomarker of host immune reserve and pretreatment risk.
DISCLOSURES
Juan Yue, PhD: No relevant conflicts of interest to declare.